Videos
Bone marrow based minimal residual disease (MRD) assessments provide greater sensitivity for residual disease detection compared to the standard serological techniques and MRD negativity is associated with improved progression-free survival (PFS). However, the frequency at which MRD can be assessed…
Videos
Dr. Stephen Harding discusses the continued partnership with the Binding Site and Dr. Sigurdur Kristinsson at the University of Iceland. Dr. Kristinsson leads the iStopMM study, and the Binding Site have analyzed more than 75,000 samples from study participants. The recent results from the iStopMM…
Videos
Background:
Cancer screening is performed worldwide for several malignancies. Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma (MM) and related lymphoproliferative disorders (LP). However, less than 5% of all MM patients are diagnosed during…
Videos
CAR T Therapy Is an Innovative and Groundbreaking Approach to Myeloma Treatment
What is CAR T therapy and how can it benefit myeloma patients?
In this video, IMF Chairman of The Board Dr. Brian G.M. Durie and IMF Chief Medical Officer Joseph Mikhael, MD, along with other myeloma experts,…
Page
For more than a decade, the International Myeloma Foundation has attended the American Society of Hematology (ASH) annual meeting, an exciting convergence of more than 30,000 health-care professionals from around the world. Explore this page to learn about the latest blood cancer research from the…
News Article
On December 29, 2021, the Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of teclistamab for the treatment of patients with relapsed or…
Videos
The bortezomib, lenalidomide, and dexamethasone (VRd) regimen is an acceptable standard of care (SoC) for both transplant-eligible and transplant-ineligible newly diagnosed multiple myeloma (TI NDMM). Ongoing development of novel therapies and combinations strive to improve survival outcomes beyond…
Videos
Extra copies of the long arm of chromosome 1 (+1q) and deletion of its short arm (del1p) are associated with high risk features in multiple myeloma (MM), but the prognostic impact of +1q and/or del1p among pts with conventionally defined standard risk cytogenetics is unclear. Whether treatment with…
Videos
Chimeric antigen receptor T cells (CAR T cells) targeting B cell maturation antigen (BCMA) have demonstrated rapid and deep responses among patients with multi-agent refractory multiple myeloma (MM). BCMA is shed from tumor cells mediated through enzymatic cleavage by the gamma secretase complex,…
Videos
DARA is approved for NDMM and previously treated MM. In the primary analysis of the phase 2 GRIFFIN trial (NCT02874742) in autologous stem cell transplant (ASCT)-eligible NDMM pts (median follow-up, 13.5 mo), DARA plus RVd (D-RVd) improved the rate of stringent complete response (sCR) by the end of…
Videos
Multiple myeloma (MM) remains an all but incurable plasma cell malignancy. Patients with relapsed MM are treated with a growing list of multi-drug regimens that typically result in transient responses followed by subsequent lines of therapy, ultimately leading to multidrug resistance. Accordingly,…
Videos
Multiple myeloma (MM) patients have an increased risk of severe coronavirus disease 2019 (COVID-19) when infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Monoclonal gammopathy of undetermined significance (MGUS) precedes MM and related disorders and affects 4.2% of the…
Videos
The Spanish Myeloma Group (GEM) demonstrated that post-transplant maintenance with thalidomide plus bortezomib was superior to thalidomide alone, although this combination was associated with a high rate of peripheral neuropathy. Lenalidomide is currently the standard postransplant maintenance…
Videos
Multiple myeloma (MM) patients are immunocompromised due to defects in humoral/cellular immunity and immunosuppressive therapy. Reports indicate that the antibody (Ab) response in MM after 1 dose of SARS-CoV-2 RNA vaccine is attenuated. The impact of treatment on cellular immunity after vaccination…
Videos
Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell disorder preceding multiple myeloma and related disorders, present in 4.2% of the population over the age of 50. Although usually asymptomatic, MGUS has been associated with various health-related problems, including…
Videos
Single-agent belantamab mafodotin (belamaf), a B-cell maturation antigen-targeting antibody-drug conjugate, achieved durable responses with a manageable safety profile in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM) in the Phase 2 DREAMM-2 trial (NCT03525678). The…
Videos
Induction therapy followed by autologous stem cell transplantation (ASCT) before maintenance is the standard of care for transplant eligible NDMM patients. The addition of daratumumab to bortezomib, thalidomide, and dexamethasone (VTD) improved response rates and reduced the risk of progression or…
Videos
Idecabtagene vicleucel (ide-cel, bb2121) is the first chimeric antigen receptor (CAR) T cell therapy approved for the treatment of relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38…
Videos
Minimal/measurable residual disease (MRD) post initial therapy is prognostic of long term outcomes in patients (pts) with newly diagnosed MM (NDMM), but has not been used to modify therapy. We hypothesized that the combination of daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd)…
Videos
Do patients with MGUS have a higher risk of contracting COVID-19 or experience more severe symptoms when infected?
In this episode, myeloma expert Dr. Brian G.M. Durie discusses if patients with MGUS are at higher risk of contracting COVID-19 or at an increased risk of having severe COVID-…
Videos
Although advances in the treatment of multiple myeloma (MM) have contributed to improved survival, treatment patterns and outcomes among patients with t(11;14) MM remain unknown. Chromosome translocation t(11;14) occurs in 15 – 20% of patients with MM and is regarded as a standard risk cytogenetic…
Videos
Prognosis is poor for patients (pts) with relapsed/refractory multiple myeloma (RRMM; median overall survival: less than 1 year), indicating a clear need to identify agents with novel mechanisms of action. B-cell maturation antigen (BCMA) has recently emerged as a novel treatment target for MM due…
Videos
BELLINI (NCT02755597) is a Phase 3, randomized, double-blind, multicenter study of Ven or Pbo combined with bortezomib and dexamethasone in pts with RRMM who had received 1–3 prior lines of therapy and were either sensitive or naïve to proteasome inhibitors. Pts were randomized 2:1 to receive Ven…
Videos
In newly-diagnosed multiple myeloma (NDMM), lenalidomide/bortezomib/dexamethasone (RVd) is one of the most widely used combination regimens. Anti-CD38 monoclonal antibodies (CD38-moAb) increase efficacy when added to standard-of-care regimens. Here we present the first primary endpoint of the…
Videos
Despite recent advances, MM remains incurable and new therapeutic options are needed, particularly for pts with RRMM. IBER is a novel, potent oral cereblon E3 ligase modulator (CELMoD®) compound with enhanced tumoricidal and immune-stimulatory effects compared with immunomodulatory (IMiD®) agents.…
Videos
In addition to serum protein electrophoresis (SPEP) and serum immunofixation (IFE), measurement of serum free light chains (FLC) has become the hallmark for detection, prognostication, and monitoring of monoclonal gammopathies. However, serum FLC levels are heavily dependent on kidney function due…
Videos
Smoldering multiple myeloma (SMM) is an asymptomatic precursor condition to multiple myeloma (MM). Emerging data from clinical trials indicate that – compared to watchful monitoring – initiation of therapy at the SMM stage might be indicated. Currently, there is no established screening for SMM in…
News Article
Member organizations gather for a successful virtual meeting
By Serdar Erdoğan
IMF Director, GMAN and European & Middle Eastern Patient Programs
On December 15, 2021, representatives of the Global Myeloma Action Network® (GMAN®) member organizations…
Videos
Modakafusp alfa (previously known as TAK-573) is a first-in-class immunocytokine designed to deliver interferon alpha-2b (IFNα2b) to CD38+ cells. It consists of two attenuated IFNα2b molecules genetically fused to the Fc portion of a humanized, anti-CD38, IgG4 monoclonal antibody (mAb). The…
Videos
Infections are a significant cause of morbidity and mortality in patients with Multiple Myeloma (MM). In Latin America, data on infectious complications in this patient population are lacking. Recommendations for antibacterial prophylaxis during current standard treatment are heterogeneous.…
Videos
Despite recent advances in treatment, patients with multiple myeloma (MM) continue to relapse. G protein-coupled receptor family C group 5 member D (GPRC5D) is a promising target for immunotherapy in patients with MM due to its high expression in malignant plasma cells and limited expression in…
Videos
Treatment of multiple myeloma (MM) has greatly improved over the last two decades. However, most pts will relapse and develop refractory disease. Most anti-cancer regimens require dose modifications (interruption, reduction, or discontinuation) during the treatment course in order to optimize the…
Videos
Multiple myeloma (MM) evolves from monoclonal gammopathy of undetermined significance (MGUS), a clinically detectable but asymptomatic premalignant phase seen in ~3% of the general population 50 years of age or older. The prevalence of MGUS has not been described in a population at high risk of…
Event
In 2010 I was diagnosed with multiple myeloma. For the past five years I have participated in a Holiday Boutique selling handknit products to raise money for myeloma research.
Videos
Dr. Noemi Puig Discusses Findings From the GEM2012MENOS65 Clinical Trial Presented at the 2021 ASH Meeting.
In this video, Dr. Noemi Puig outlines how next generation flow cytometry (NGF) and next generation sequencing have shown an increased capacity to identify the presence of myeloma…
Videos
ASH 2021: Making Sense of Treatment
In this segment of the IMWG Conference Series, “Making Sense of Treatment,” leading myeloma experts discuss the latest drug therapy news from the annual American Society of Hematology (ASH) conference. Moderated by IMF Chairman of the Board Dr. Brian G.M.…
Videos
Dr. Thomas Martin Discusses Long Duration Follow-Up of CARTITUDE-1 Presented at ASH 2021.
In this video, Dr. Thomas Martin discusses the CARTITUDE-1 trial and cilta-cel, presented at ASH 2021.
About CARTITUDE-1 and cilta-cel
Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen…
Videos
Jon Þórir Oskarsson, MSC Discusses the First Study To Evaluate CTPC in Patients With Myeloma Precursor Conditions.In this video, Jon Þórir Oskarsson, MSc, discusses the first study to evaluate CTPC in patients with myeloma precursor conditions.What is the purpose of this study?The purpose is to…
Videos
Dr. Jeffrey Zonder talks about the early, deep, and durable responses with REGN5458In this video, Dr. Jeffrey Zonder talks about the early, deep, and durable responses, and low rates of cytokine release syndrome (CRS) with REGN5458.What is REGN5458?REGN5458 is a BCMA Bispecific Monoclonal…
Videos
Join us for this live symposium featuring discussion of patient case studies and key clinical trial data by renowned clinical experts providing their perspectives on recent advances in the treatment of multiple myeloma.…
Videos
How are the four iStopMM abstracts being presented at the 2021 ASH meeting relevant to myeloma patients?
In this episode, myeloma expert Dr. Brian G.M. Durie discusses the 4 iStopMM abstracts being presented at the ASH 2021 meeting.
The BOTTOM LINE: While these are early…
Event
Dr. Brian G.M. Durie discusses important takeaways relating to multiple myeloma from the annual American Society of Hematology (ASH) conference
Register now
Videos
Should Myeloma Patients Change Treatment Before Getting Vaccinated Against Covid-19?
In this episode, Dr. Brian G.M. Durie discusses if myeloma patients should alter their treatment regimen to attempt to achieve a better response from the Covid-19 vaccination.
The BOTTOM Line:…
Videos
Virtual Multiple Myeloma Community Workshop A virtual multiple myeloma workshop addressing the needs specific to communities in the state of Florida.The IMF Virtual Regional Community Workshop will include an introduction to myeloma, upfront treatments at diagnosis, maintenance therapy,…
Videos
What are the upcoming oral medications that will be used against COVID-19?
In this episode, myeloma expert Dr. Brian G.M. Durie outlines the upcoming oral medications against COVID-19 and how they can be used to reduce severe infection and hospitalization in myeloma patients.
The…
Videos
M-Power Atlanta Community Workshop discusses:
Learn about multiple myeloma, a disease more than twice as common in people of African descent as in whites. From “Myeloma for Patients Who Are Just Getting Started” to the latest in…
News Article
Los Angeles, CA, November 12, 2021 –The International Myeloma Foundation (IMF) announced today that Yelak Biru, 51, a longtime myeloma patient advocate and former Data and Analytics Executive at PepsiCo and Walmart, has been named Chief Executive Officer of the nonprofit research…
Videos
Have Questions About Myeloma? The IMF InfoLine Team Has Answers.
Find out how we are here for you.
Someone who's been diagnosed with myeloma has a million questions. The IMF’s InfoLine Team is here to answer your questions in a caring and compassionate manner. Learn more about how the IMF's…
Videos
Which Covid-19 Booster Should Myeloma Patients Get?
Myeloma expert Dr. Brian G.M. Durie talks COVID-19 boosters and which is best for patients with multiple myeloma.
The BOTTOM LINE: Myeloma patients are recommended to get a booster shot. Talk to your doctor about the pros and cons of…
Event
A virtual multiple myeloma workshop addressing the needs specific to communities in the state of Florida.